Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.42 |
| ▸ | EPOR | P19235 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4728840 | 1.00 | GSR (0.46) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL29067246 | 0.83 | GRIK1 (0.41) | GSRRNPEPCPB2GRIK1GRIK2 | |
| SCHEMBL4298060 | 0.81 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL4298056 | 0.81 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL11013496 | 0.81 | SLC6A5 (0.43) | GSRRNPEPCPB2GRIK1GRIK2 | |
| SCHEMBL28509039 | 0.80 | GSR (0.47) | GSRRNPEPCPB2FOLH1GABRR1 | |
| SCHEMBL6267879 | 0.80 | GSR (0.47) | GSRRNPEPCPB2FOLH1GABRR1 | |
| SCHEMBL2725758 | 0.78 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL634033 | 0.78 | GSR (0.48) | GSRRNPEPCPB2EPORFOLH1 | |
| SCHEMBL6739029 | 0.77 | CPB2 (0.45) | GSRRNPEPCPB2FOLH1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100584-A1 | BEER-FLAVORED BEVERAGE AND METHOD FOR PRODUCING SAME | キリンホールディングス株式会社 | 2026-05-15 | — | — | WO | claimed |
| US-20250250331-A1 | ANTI-AGE ANTIBODIES FOR TREATING NEURODEGENERATIVE DISORDERS | SIWA CORP (US) | 2025-08-07 | — | — | US | claimed |
| WO-2025083830-A1 | NON-ALCOHOLIC BEER-FLAVORED BEVERAGE HAVING ENHANCED RICHNESS | キリンホールディングス株式会社 | 2025-04-24 | — | — | WO | claimed |
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | UNIVERSITY OF SOUTH CAROLINA | 2025-01-23 | — | — | US | claimed |
| CN-119331874-A | Carboxymethyl lysine and carboxyethyl lysine aptamer based on efficient microfluidic SELEX platform screening | 江南大学 | 2025-01-21 | — | — | CN | claimed |
| WO-2025005235-A1 | BEER-FLAVORED ALCOHOLIC BEVERAGE AND METHOD FOR PRODUCING SAME | キリンホールディングス株式会社 | 2025-01-02 | — | — | WO | claimed |
| WO-2024225456-A1 | BEER-FLAVORED ALCOHOLIC BEVERAGE AND PRODUCTION METHOD THEREFOR | キリンホールディングス株式会社 | 2024-10-31 | — | — | WO | claimed |
| EP-4388016-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | Siwa Corporation (US) | 2024-06-26 | — | — | EP | claimed |
| WO-2024122615-A1 | BEER-FLAVORED ALCOHOLIC BEVERAGE AND PRODUCTION METHOD FOR SAME | キリンホールディングス株式会社 | 2024-06-13 | — | — | WO | claimed |
| WO-2024102157-A1 | METHODS AND COMPOSITIONS FOR TREATING DIABETES AND DIABETIC COMPLICATIONS | SIWA CORPORATION (US) | 2024-05-16 | — | — | WO | claimed |
| US-20160175413-A1 | METHOD AND COMPOSITION FOR TREATING SARCOPENIA | SIWA CORPORATION | 2016-06-23 | — | — | US | claimed |
| US-20140224737-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| EP-2547379-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | Fresenius Medical Care Deutschland GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| US-20130011364-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) | 2013-01-10 | — | — | US | claimed |
| WO-2011113607-A1 | MOLECULARLY IMPRINTED POLYMERS FOR ELIMINATING METABOLITES | FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| WO-2005037990-A2 | USE OF PARP INHIBITORS FOR PREVENTION AND TREATMENT OF DIABETIC AND INSULIN RESISTANCE COMPLICATIONS | ALBERT EINSTEIN COLLEGE OF MEDECINE OF YESHIVA UNIVERSITY (US) | 2005-04-28 | — | — | WO | claimed |
| EP-1023080-A4 | LIGAND BINDING SITE OF RAGE AND USES THEREOF | UNIV COLUMBIA (US) | 2003-03-19 | — | — | EP | claimed |
| US-20010053357-A1 | LIGAND BINDING SITE OF RAGE AND USES THEREOF | TRANSTECH PHARMA, INC. | 2001-12-20 | — | — | US | claimed |
| EP-1023080-A1 | LIGAND BINDING SITE OF RAGE AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1999018987-A1 | LIGAND BINDING SITE OF RAGE AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1999-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025560-A1 | METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF | L1CAM, CD274, PDCD1LG2 | GSR 592/4885RNPEP 1788/4885CPB2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.